ArticleJournal of intensive care2026
Outcomes of combined carbazochrome sodium sulfonate plus tranexamic acid therapy versus tranexamic acid monotherapy in traumatic brain injury: a retrospective cohort study in Japan.
Article in Journal of intensive care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundTraumatic brain injury (TBI) is a major public health concern associated with substantial morbidity and mortality. In Japan, carbazochrome sodium sulfonate (CSS) is widely used, often in combination with tranexamic acid (TXA), for the management of various types of bleeding; however, studies on the effectiveness of CSS in TBI are scarce. Therefore, this study aimed to investigate the association between the use of CSS plus TXA versus TXA alone and the clinical outcomes in patients with TBI.
methodsThis observational study was conducted using data retrieved from the Japanese Diagnosis Procedure Combination database between July 2010 and March 2022. We enrolled adult patients aged ≥ 16 years diagnosed with TBI who received TXA on the day of admission. Patients with chronic subdural hematoma, suspected TBI diagnosis, or severe extracranial trauma were excluded. The exposure was CSS plus TXA administration on the day of admission, with TXA monotherapy assigned as the control. The primary outcome was 28-day in-hospital mortality, and the secondary outcomes were 7-day in-hospital mortality, overall in-hospital mortality, consciousness at discharge, and length of hospital stay. We used propensity-score overlap weighting to balance patient characteristics between the groups.
resultsThis study included 150,026 patients. Of these, 17,212 (11.5%) received TXA alone, and 132,814 (88.5%) received CSS plus TXA. After propensity score overlap weighting, the primary outcome did not differ significantly between the TXA-only and CSS plus TXA groups (11.7% vs. 11.9%; risk difference, 0.1%; 95% CI - 0.4 to 0.7%). The secondary outcomes were also comparable between the two groups. However, the subgroup analysis restricted to unarousable patients (Japan Coma Scale 100-300) revealed a significant reduction in the 7-day mortality in the CSS plus TXA group.
conclusionsCombined treatment with CSS and TXA was not associated with better clinical outcomes in terms of in-hospital mortality, consciousness at discharge, or length of hospital stay in hospitalized adult patients with TBI compared with TXA therapy alone. Routine use of CSS may not be recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.